ASAH2B | N-acylsphingosine amidohydrolase (non-lysosomal ceramidase) 2B | | | | | | Tissue enhanced |
ASAH2C | N-acylsphingosine amidohydrolase (non-lysosomal ceramidase) 2C | Enzymes
| | | | | Group enriched |
ASIC5 | Acid-sensing (proton-gated) ion channel family member 5 | Predicted membrane proteins
| | | | | Tissue enhanced |
ATOH1 | Atonal homolog 1 (Drosophila) | Cancer-related genes Plasma proteins Transcription factors
| | | | | Group enriched |
ATP10B | ATPase, class V, type 10B | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
ATP4A | ATPase, H+/K+ exchanging, alpha polypeptide | Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enriched |
ATP4B | ATPase, H+/K+ exchanging, beta polypeptide | Predicted membrane proteins Transporters
| | | | | Tissue enriched |
B3GALT1 | UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 1 | Predicted secreted proteins
| | | | | Tissue enhanced |
B3GALT5 | UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 5 | Predicted secreted proteins
| | | | | Tissue enhanced |
B3GNT3 | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3 | Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
B3GNT6 | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 6 (core 3 synthase) | Predicted secreted proteins
| | | | | Tissue enhanced |
B3GNT7 | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 | Predicted secreted proteins
| | | | | Tissue enhanced |
B4GALNT2 | Beta-1,4-N-acetyl-galactosaminyl transferase 2 | Predicted membrane proteins
| | | | | Tissue enhanced |
B4GALNT3 | Beta-1,4-N-acetyl-galactosaminyl transferase 3 | Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
BAIAP2L2 | BAI1-associated protein 2-like 2 | | | | | | Tissue enhanced |
BARX1 | BARX homeobox 1 | Transcription factors
| | | | | Tissue enriched |
BCAS1 | Breast carcinoma amplified sequence 1 | | | | | | Tissue enhanced |
BCL2L15 | BCL2-like 15 | | | | | | Group enriched |
BCMO1 | Beta-carotene 15,15'-monooxygenase 1 | Disease related genes Enzymes Potential drug targets
| | | | | Tissue enhanced |
BEST2 | Bestrophin 2 | Predicted membrane proteins Transporters
| | | | | Group enriched |
BEST4 | Bestrophin 4 | Predicted membrane proteins
| | | | | Group enriched |
BPIFB1 | BPI fold containing family B, member 1 | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
BRINP3 | Bone morphogenetic protein/retinoic acid inducible neural-specific 3 | Predicted secreted proteins
| | | | | Tissue enhanced |
BTNL3 | Butyrophilin-like 3 | Predicted membrane proteins
| | | | | Group enriched |
BTNL8 | Butyrophilin-like 8 | Predicted membrane proteins
| | | | | Group enriched |
C10orf129 | Chromosome 10 open reading frame 129 | Enzymes Mitochondrial proteins Predicted membrane proteins
| | | | | Tissue enhanced |
C10orf99 | Chromosome 10 open reading frame 99 | Predicted secreted proteins
| | | | | Group enriched |
C11orf86 | Chromosome 11 open reading frame 86 | | | | | | Group enriched |
C12orf36 | Chromosome 12 open reading frame 36 | | | | | | Group enriched |
C15orf48 | Chromosome 15 open reading frame 48 | | | | | | Tissue enhanced |
C17orf78 | Chromosome 17 open reading frame 78 | Predicted membrane proteins
| | | | | Group enriched |
C19orf69 | Chromosome 19 open reading frame 69 | | | | | | Group enriched |
C19orf77 | Chromosome 19 open reading frame 77 | Predicted membrane proteins
| | | | | Tissue enhanced |
C1orf106 | Chromosome 1 open reading frame 106 | | | | | | Tissue enhanced |
C1orf127 | Chromosome 1 open reading frame 127 | Predicted secreted proteins
| | | | | Group enriched |
C21orf88 | Chromosome 21 open reading frame 88 | | | | | | Group enriched |
C2orf70 | Chromosome 2 open reading frame 70 | | | | | | Group enriched |
C6orf222 | Chromosome 6 open reading frame 222 | | | | | | Tissue enhanced |
C6orf58 | Chromosome 6 open reading frame 58 | Predicted secreted proteins
| | | | | Group enriched |
C8G | Complement component 8, gamma polypeptide | Plasma proteins Predicted secreted proteins
| | | | | Group enriched |
C9orf152 | Chromosome 9 open reading frame 152 | | | | | | Tissue enhanced |
CA1 | Carbonic anhydrase I | Enzymes FDA approved drug targets Plasma proteins
| | | | | Group enriched |
CA2 | Carbonic anhydrase II | Disease related genes Enzymes FDA approved drug targets Plasma proteins
| | | | | Tissue enhanced |
CA4 | Carbonic anhydrase IV | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CA7 | Carbonic anhydrase VII | Enzymes FDA approved drug targets
| | | | | Tissue enhanced |
CA9 | Carbonic anhydrase IX | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
CACNA1A | Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
CAPN13 | Calpain 13 | Enzymes
| | | | | Group enriched |
CAPN8 | Calpain 8 | Enzymes
| | | | | Tissue enriched |
CAPN9 | Calpain 9 | Enzymes
| | | | | Tissue enhanced |